特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Chiesi Farmaceutici SpA:製品パイプライン分析

Chiesi Farmaceutici SpA - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 207932
出版日 ページ情報 英文 61 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.57円で換算しております。
Chiesi Farmaceutici SpA:製品パイプライン分析 Chiesi Farmaceutici SpA - Product Pipeline Review - 2016
出版日: 2016年10月12日 ページ情報: 英文 61 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

Chiesi Farmaceutici SpA. は研究重視の製薬会社で、呼吸器系、心血管、そして奇病に対する治療薬を研究・開発し、市場に流通させるように努力しています。

当レポートでは、Chiesi Farmaceutici SpAにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Chiesi Farmaceutici SpAの基本情報

Chiesi Farmaceutici SpAの概要

  • 主要情報
  • 企業情報

Chiesi Farmaceutici SpA:R&Dの概要

  • 主な治療範囲

Chiesi Farmaceutici SpA:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • 併用療法モダリティ
  • パートナー製品
    • パートナー製品/併用療法モダリティ
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Chiesi Farmaceutici SpA:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ

Chiesi Farmaceutici SpA▼初期段階にあるパイプライン製品

前臨床段階にある製品/併用療法モダリティ

Chiesi Farmaceutici SpA:薬剤プロファイル

  • (beclomethasone dipropionate + formoterol fumarate + glycopyrrolate)
  • meropenem
  • CHF-6001
  • glycopyrrolate
  • CHF-5633
  • Drug for Cystic Fibrosis
  • Small Molecule to Agonize Glucocorticoid Receptor for Asthma and COPD
  • Small Molecule to Inhibit Caspase-2 for Neonatal Brain Injury
  • Small Molecule to target Beta 2 Adrenergic Receptor and Muscarinic Acetylcholine Receptor M3 for Asthma and COPD
  • Small Molecules to Inhibit Neutrophil Elastases

Chiesi Farmaceutici SpA:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Chiesi Farmaceutici SpA:最近のパイプライン動向

Chiesi Farmaceutici SpA:休止中のプロジェクト

Chiesi Farmaceutici SpA:開発が中止されたパイプライン製品▼開発が中止されたパイプライン製品のプロファイル

carmoterol indantadol

Chiesi Farmaceutici SpA:企業発表

Chiesi Farmaceutici SpA:本社と子会社の所在地

付録

図表

目次
Product Code: GMDHC08152CDB

Summary

Global Markets Direct's, 'Chiesi Farmaceutici SpA - Product Pipeline Review - 2016', provides an overview of the Chiesi Farmaceutici SpA's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Chiesi Farmaceutici SpA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Chiesi Farmaceutici SpA
  • The report provides overview of Chiesi Farmaceutici SpA including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Chiesi Farmaceutici SpA's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Chiesi Farmaceutici SpA's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Chiesi Farmaceutici SpA's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chiesi Farmaceutici SpA
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chiesi Farmaceutici SpA's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Chiesi Farmaceutici SpA Snapshot
    • Chiesi Farmaceutici SpA Overview
    • Key Facts
  • Chiesi Farmaceutici SpA - Research and Development Overview
    • Key Therapeutic Areas
  • Chiesi Farmaceutici SpA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Chiesi Farmaceutici SpA - Pipeline Products Glance
    • Chiesi Farmaceutici SpA - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Chiesi Farmaceutici SpA - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Chiesi Farmaceutici SpA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
    • Chiesi Farmaceutici SpA - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Chiesi Farmaceutici SpA - Drug Profiles
    • (beclomethasone dipropionate + formoterol fumarate + glycopyrrolate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • budesonide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CHF-5633 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CHF-6001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CHF-6297 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CPD-15 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Bronchopulmonary Dysplasia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • glycopyrrolate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • melatonin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meropenem - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Enzymes for Rare Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Neonatal Respiratory Distress Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Target NGF for Undisclosed Indication - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Neutrophil Elastase for Respiratory Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target Beta 2 Adrenergic Receptor and Muscarinic Acetylcholine Receptor M3 for Asthma and COPD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Neonatal Abstinence Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRP-601 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • velmanase alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chiesi Farmaceutici SpA - Pipeline Analysis
    • Chiesi Farmaceutici SpA - Pipeline Products by Target
    • Chiesi Farmaceutici SpA - Pipeline Products by Route of Administration
    • Chiesi Farmaceutici SpA - Pipeline Products by Molecule Type
    • Chiesi Farmaceutici SpA - Pipeline Products by Mechanism of Action
  • Chiesi Farmaceutici SpA - Dormant Projects
  • Chiesi Farmaceutici SpA - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • beclomethasone dipropionate SR
      • carmoterol
      • indantadol
      • Porphozym
  • Chiesi Farmaceutici SpA - Company Statement
  • Chiesi Farmaceutici SpA - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Chiesi Farmaceutici SpA, Key Facts
  • Chiesi Farmaceutici SpA - Pipeline by Indication, 2016
  • Chiesi Farmaceutici SpA - Pipeline by Stage of Development, 2016
  • Chiesi Farmaceutici SpA - Monotherapy Products in Pipeline, 2016
  • Chiesi Farmaceutici SpA - Combination Treatment Modalities in Pipeline, 2016
  • Chiesi Farmaceutici SpA - Partnered Products in Pipeline, 2016
  • Chiesi Farmaceutici SpA - Partnered Products/ Combination Treatment Modalities, 2016
  • Chiesi Farmaceutici SpA - Out-Licensed Products in Pipeline, 2016
  • Chiesi Farmaceutici SpA - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Chiesi Farmaceutici SpA - Phase III, 2016
  • Chiesi Farmaceutici SpA - Phase II, 2016
  • Chiesi Farmaceutici SpA - Phase I, 2016
  • Chiesi Farmaceutici SpA - Preclinical, 2016
  • Chiesi Farmaceutici SpA - Unknown, 2016
  • Chiesi Farmaceutici SpA - Pipeline by Target, 2016
  • Chiesi Farmaceutici SpA - Pipeline by Route of Administration, 2016
  • Chiesi Farmaceutici SpA - Pipeline by Molecule Type, 2016
  • Chiesi Farmaceutici SpA - Pipeline Products by Mechanism of Action, 2016
  • Chiesi Farmaceutici SpA - Dormant Developmental Projects,2016
  • Chiesi Farmaceutici SpA - Discontinued Pipeline Products, 2016
  • Chiesi Farmaceutici SpA, Subsidiaries

List of Figures

  • Chiesi Farmaceutici SpA - Pipeline by Top 10 Indication, 2016
  • Chiesi Farmaceutici SpA - Pipeline by Stage of Development, 2016
  • Chiesi Farmaceutici SpA - Monotherapy Products in Pipeline, 2016
  • Chiesi Farmaceutici SpA - Combination Treatment Modalities in Pipeline, 2016
  • Chiesi Farmaceutici SpA - Out-Licensed Products in Pipeline, 2016
  • Chiesi Farmaceutici SpA - Pipeline by Top 10 Target, 2016
  • Chiesi Farmaceutici SpA - Pipeline by Route of Administration, 2016
  • Chiesi Farmaceutici SpA - Pipeline by Molecule Type, 2016
  • Chiesi Farmaceutici SpA - Pipeline Products by Top 10 Mechanism of Action, 2016